Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Context Therapeutics Inc
(NQ:
CNTX
)
1.390
-0.110 (-7.33%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Context Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 31, 2023
Gainers
Via
Benzinga
Why Context Therapeutics (CNTX) Shares Are Seeing Blue Skies
January 31, 2023
Context Therapeutics Inc (NASDAQ: CNTX) shares are trading higher by 60.32% to $1.10 Tuesday afternoon after the company announced its clinical trial collaborator, Stemline Therapeutics, received...
Via
Benzinga
Dow Turns Higher; Nasdaq Jumps 100 Points
January 31, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded up 0.19% to 33,781.23 while the NASDAQ rose 0.90% to 11,496.13. The S&P...
Via
Benzinga
What About Women? This Company Targets Female-Focused Cancers
January 31, 2022
Photo sourced from Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
January 31, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
$1 Million Bet On Motorsport Games? Check Out These 4 Penny Stocks Insiders Are Buying
January 31, 2023
The Nasdaq dropped more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...
Via
Benzinga
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
January 24, 2023
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
January 19, 2023
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
January 09, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
January 04, 2023
From
Context Therapeutics Inc.
Via
GlobeNewswire
Why Context Therapeutics Stock Is Falling 25% Today
December 08, 2022
Context Therapeutics Inc (NASDAQ: CNTX) shares are trading lower by 26.62% to $1.02 during Thursday's session after the company reported preliminary Phase 2 data for ONA-XR metastatic breast cancer....
Via
Benzinga
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
December 08, 2022
From
Context Therapeutics Inc.
Via
GlobeNewswire
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
December 08, 2022
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.
Via
Benzinga
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
November 29, 2022
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
November 21, 2022
Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Partners With Integral Molecular To Develop An Emerging Cancer Drug
November 10, 2022
Context Therapeutics Inc. (NASDAQ: CNTX) and Integral Molecular are teaming up to develop an anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for cancer therapy.
Via
Benzinga
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
November 09, 2022
From
Context Therapeutics Inc.
Via
GlobeNewswire
New Ammo In The Battle Against Cancer – Context Therapeutics Sees Promising Results For Several Novel Drugs
August 17, 2022
Martin Lehr, Co-Founder and CEO of Contect Therapeutics, Inc (NASDAQ: CNTX), was a guest on Benzinga’s All Access on Aug 12, 2022.
Via
Benzinga
69 Biggest Movers From Friday
June 06, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...
Via
Benzinga
40 Stocks Moving In Friday's Mid-Day Session
June 03, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Via
Benzinga
66 Biggest Movers From Friday
May 23, 2022
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
Via
Benzinga
35 Stocks Moving In Monday's Mid-Day Session
April 04, 2022
Gainers Aterian, Inc. (NASDAQ: ATER) shares jumped 43.5% to $3.3457. Aterian said Cynthia Williams has joined the Company's Board of Directors. Jumia Technologies AG (...
Via
Benzinga
68 Biggest Movers From Yesterday
April 05, 2022
Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
April 04, 2022
If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today.
Via
InvestorPlace
26 Stocks Moving in Monday's Pre-Market Session
April 04, 2022
Gainers SPI Energy Co., Ltd. (NASDAQ: SPI) rose 36.3% to $3.87 in pre-market trading after reporting record revenue of $162 million for 2021. Twitter, Inc. (NYSE: TWTR) rose...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
February 02, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...
Via
Benzinga
45 Biggest Movers From Yesterday
December 29, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares climbed 64.8% to close at $19.02 on Tuesday as traders circulated a social media post on a potential short squeeze. ShiftPixy...
Via
Benzinga
25 Stocks Moving In Tuesday's Mid-Day Session
December 28, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 64.6% to $18.99 as traders circulated a social media post on a potential short squeeze. Flotek Industries, Inc. (NYSE...
Via
Benzinga
32 Stocks Moving In Wednesday's Mid-Day Session
December 22, 2021
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 31.7% to $2.41 after the company announced it was awarded a multiple award blanket purchase agreement by the United...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
December 22, 2021
We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.